



Astec LifeSciences Ltd.

Date: 27th April, 2026

To,
BSE Limited
P. J. Towers, Dalal Street, Fort,
Mumbai – 400 001

To,
National Stock Exchange of India Limited
Exchange Plaza, Bandra - Kurla Complex,
Bandra (East), Mumbai – 400 051

Ref.: BSE Scrip Code No. “533138”

Ref.: “ASTEC”

Debt Segment NSE:
NCD-ASTEC-ISIN: INE563J08023

Sub.: Outcome of the Board Meeting

Pursuant to Regulations 30, 33 and 52(4) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) read with Schedule III to the said Regulations, this is to inform you that the Board of Directors of the Company, at its Meeting held today, i.e., on **Monday, 27th April, 2026** (which commenced at 3.15 p.m. and concluded at 5.45 p.m.), *inter alia*, has approved / noted the following:

(a) APPROVAL OF THE AUDITED FINANCIAL RESULTS (STANDALONE AND CONSOLIDATED) FOR THE QUARTER AND FINANCIAL YEAR ENDED 31ST MARCH, 2026:

Upon recommendation of the Audit Committee, the Board of Directors has approved the Audited Financial Results (Standalone & Consolidated) as per Indian Accounting Standards (IND AS) for the Quarter and Financial Year ended 31st March, 2026 along with Cash Flow Statement and the Statement of Assets and Liabilities as on 31st March, 2026. The same are enclosed herewith.

(b) NOTING OF THE STATUTORY AUDITORS’ REPORTS ON THE AUDITED FINANCIAL RESULTS (STANDALONE & CONSOLIDATED) FOR THE QUARTER AND FINANCIAL YEAR ENDED 31ST MARCH, 2026:

Upon recommendation of the Audit Committee, the Board of Directors took note of the Statutory Auditors’ Reports on the Audited Financial Results (Standalone & Consolidated) for the Quarter and Financial Year ended 31st March, 2026. The same are enclosed herewith.

The Reports of Statutory Auditors are with unmodified opinion with respect to the Audited Financial Results (Standalone and Consolidated) of the Company for the Quarter and Financial Year ended 31st March, 2026.

(c) AGM RELATED MATTERS:

The Board considered and fixed the date of the 32nd (Thirty-Second) Annual General Meeting and related matters as under:

- (i) The 32nd (Thirty-Second) Annual General Meeting of the Shareholders of the Company will be held on Friday, 31st July, 2026 at 4.00 p.m.



Regd. Office :
“Godrej One”, 3rd Floor,
Pirojshanagar, Eastern Express Highway,
Vikhroli (East), Mumbai - 400079,
Maharashtra, India
Telephone No. : 022-22618289
Fax No. : 022-22618289
Email id : astecinfo@godrejastec.com
Website : www.godrejastec.com
CIN : L99999MH1994PLC076236



Astec LifeSciences Ltd.

- (ii) The Book Closure Dates for the purposes of the 32nd (Thirty-Second) Annual General Meeting are from Sunday, 26th July, 2026 to Thursday, 30th July, 2026, during which the Register of Members and Share Transfer Books will remain closed.

(d) PROPOSAL TO SEEK APPROVAL OF THE SHAREHOLDERS FOR CERTAIN MATTERS BY WAY OF POSTAL BALLOT:

We would like to inform that the Board of Directors, at its Meeting held today, has approved the proposal to seek the consent of the Shareholders in respect of following matters, by way of Postal Ballot:

1. Appointment of Mr. Vishal Sharma, Additional Director as a “Non-Executive Director” liable to retire by rotation;
2. Appointment of Mr. Burjis N. Godrej, Additional Director as a “Non-Executive Director” liable to retire by rotation;
3. Appointment and Remuneration of Mr. Arijit Mukherjee as a “Executive Director” (while continuing to be Chief Operating Officer);
4. Appointment of Mr. Mathew Eipe as an “Independent Director”;
5. Approval for entering into Material Related Party Transactions during the Financial Year 2026-27.

The above information is also being uploaded on the Company’s website, viz., www.godrejastec.com.

Please take the above information on your records.

Thanking you,

Yours sincerely,

For Astec LifeSciences Limited

**Tejashree Pradhan
Company Secretary & Compliance Officer
(FCS 7167)**

Encl.: As above



Regd. Office :
“Godrej One”, 3rd Floor,
Pirojshanagar, Eastern Express Highway,
Vikhroli (East), Mumbai - 400079,
Maharashtra, India
Telephone No. : 022-25188010
Fax No. : 022-22618289
Email id : astecinfo@godrejastec.com
Website : www.godrejastec.com
CIN : L99999MH1994PLC076236

Independent Auditor's Report

To the Board of Directors of Astec LifeSciences Limited

Report on the audit of the Standalone Annual Financial Results

Opinion

We have audited the accompanying standalone annual financial results of Astec LifeSciences Limited (hereinafter referred to as the "Company") for the year ended 31 March 2026, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 and Regulation 52(4) read with Regulation 63 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"), as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone annual financial results:

- a. are presented in accordance with the requirements of Regulation 33 and Regulation 52(4) read with Regulation 63 of the Listing Regulations, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021 in this regard; and
- b. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, and other accounting principles generally accepted in India, of the net loss and other comprehensive income and other financial information for the year ended 31 March 2026.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the *Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results* section of our report. We are independent of the Company, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us, is sufficient and appropriate to provide a basis for our opinion on the standalone annual financial results.

Management's and Board of Directors' Responsibilities for the Standalone Annual Financial Results

These standalone annual financial results have been prepared on the basis of the standalone annual financial statements.

The Company's Management and the Board of Directors are responsible for the preparation and presentation of these standalone annual financial results that give a true and fair view of the net profit/loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52(4) read with Regulation 63 of the Listing Regulations, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting

Registered Office:

Independent Auditor's Report (Continued)

Astec LifeSciences Limited

frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone annual financial results, the Management and the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the standalone annual financial results made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management's and Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone annual financial results, including the disclosures, and whether the standalone annual financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Independent Auditor's Report (Continued)

Astec LifeSciences Limited

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

- a. The standalone annual financial results include the results for the quarter ended 31 March 2026 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.:101248W/W-100022

**Rahul
Choudhary**

Digitally signed by
Rahul Choudhary
Date: 2026.04.27
18:01:07 +05'30'

Rahul Choudhary

Partner

Mumbai

27 April 2026

Membership No.: 408408

UDIN:26408408YKKNYMM9964

Independent Auditor's Report

To the Board of Directors of Astec LifeSciences Limited

Report on the audit of the Consolidated Annual Financial Results

Opinion

We have audited the accompanying consolidated annual financial results of Astec LifeSciences Limited (hereinafter referred to as the "Holding Company") and its subsidiaries (Holding Company and its subsidiaries together referred to as "the Group"), for the year ended 31 March 2026, attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 and Regulation 52(4) read with Regulation 63 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"), as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021.

In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of report of other auditor on separate financial statements of the subsidiary, the aforesaid consolidated annual financial results:

- a. include the annual financial results of the entities mentioned in Annexure I to the aforesaid consolidated annual financial results;
- b. are presented in accordance with the requirements of Regulation 33 and Regulation 52(4) read with Regulation 63 of the Listing Regulations, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021 in this regard; and
- c. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, and other accounting principles generally accepted in India, of consolidated net loss and other comprehensive income and other financial information of the Group for the year ended 31 March 2026.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the *Auditor's Responsibilities for the Audit of the Consolidated Annual Financial Results* section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us along with the consideration of report of the other auditor referred to in sub paragraph no. (a) of the "Other Matters" paragraph below, is sufficient and appropriate to provide a basis for our opinion on the consolidated annual financial results.

Management's and Board of Directors' Responsibilities for the Consolidated Annual Financial Results

These consolidated annual financial results have been prepared on the basis of the consolidated annual financial statements.

The Holding Company's Management and the Board of Directors are responsible for the preparation and presentation of these consolidated annual financial results that give a true and fair view of the consolidated

Registered Office:

Independent Auditor's Report (Continued)

Astec LifeSciences Limited

net profit/ loss and other comprehensive income and other financial information of the Group in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52(4) read with Regulation 63 of the Listing Regulations, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021. The respective Management and Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of each company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated annual financial results by the Management and the Board of Directors of the Holding Company, as aforesaid.

In preparing the consolidated annual financial results, the respective Management and the Board of Directors of the companies included in the Group are responsible for assessing the ability of each company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the company or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group is responsible for overseeing the financial reporting process of each company.

Auditor's Responsibilities for the Audit of the Consolidated Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the consolidated annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the consolidated annual financial results made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management's and Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on

Independent Auditor's Report (Continued)

Astec LifeSciences Limited

the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the consolidated annual financial results, including the disclosures, and whether the consolidated annual financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities within the Group to express an opinion on the consolidated annual financial results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the consolidated annual financial results of which we are the independent auditor. For the other entities included in the consolidated annual financial results, which have been audited by other auditor, such other auditor remain responsible for the direction, supervision and performance of the audit carried out by them. We remain solely responsible for our audit opinion. Our responsibilities in this regard are further described in sub paragraph no. (a) of the "Other Matters" paragraph in this audit report.

We communicate with those charged with governance of the Holding Company and such other entities included in the consolidated annual financial results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular No CIR/CFD/CMD1/44/2019 issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

Other Matters

- a. The consolidated annual financial results include the audited financial results of one subsidiary, whose financial results reflects total assets (before consolidation adjustments) of Rs. 161.27 lakhs as at 31 March 2026, total revenue (before consolidation adjustments) of Rs. 19.01 lakhs and total net profit after tax (before consolidation adjustments) of Rs. 12.02 lakhs and net cash inflows (before consolidation adjustments) of Rs 0.13 lakhs for the year ended on that date, as considered in the consolidated annual financial results, which has been audited by its independent auditor. The independent auditor's report on financial results of this entity has been furnished to us by the management.

Our opinion on the consolidated annual financial results, in so far as it relates to the amounts and disclosures included in respect of this entity, is based solely on the report of such auditor and the procedures performed by us are as stated in paragraph above.

Our opinion on the consolidated annual financial results is not modified in respect of the above matter with respect to our reliance on the work done and the report of the other auditor.

- b. The consolidated annual financial results include the unaudited financial results of one subsidiary, whose financial information reflects total assets (before consolidation adjustments) of Rs. 0.22 lakhs as at 31 March 2026, total revenue (before consolidation adjustments) of Rs. Nil lakhs, total net profit after tax (before consolidation adjustments) of Rs. Nil lakhs and net cash inflows (before consolidation adjustments) of Rs 0.04 lakhs for the year ended on that date, as considered in the consolidated annual financial results. This unaudited financial information has been furnished to us by the Board

Independent Auditor's Report (Continued)
Astec LifeSciences Limited

of Directors.

Our opinion on the consolidated annual financial results, in so far as it relates to the amounts and disclosures included in respect of this subsidiary, is based solely on such financial information. In our opinion and according to the information and explanations given to us by the Board of Directors, these financial information are not material to the Group.

Our opinion on the consolidated annual financial results is not modified in respect of the above matter with respect to the financial information certified by the Board of Directors.

- c. The consolidated annual financial results include the results for the quarter ended 31 March 2026 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.:101248W/W-100022

Rahul
Choudhary Digitally signed by
Rahul Choudhary
Date: 2026.04.27
18:02:26 +05'30'

Rahul Choudhary

Partner

Mumbai

27 April 2026

Membership No.: 408408

UDIN:26408408LOCZUN8984

Independent Auditor's Report (Continued)
Astec LifeSciences Limited

Annexure I

List of entities included in consolidated annual financial results.

Sr. No	Name of component	Relationship
1	Astec LifeSciences Limited	Holding Company
2	Behram Chemicals Private Limited	Subsidiary Company
3	Comercializadora Agricola Agroastrachem Cia Ltda	Subsidiary Company

Sr. No	Particulars	STANDALONE				
		Quarter ended			Year ended	
		31/Mar/26	31/Dec/25	31/Mar/25	31/Mar/26	31/Mar/25
		(Refer Note 5)	(Unaudited)	(Refer Note 5)	(Audited)	(Audited)
I	Revenue from Operations	15,862.27	12,472.03	11,952.70	44,814.56	38,130.35
II	Other Income	261.41	79.36	77.72	498.87	555.81
III	Total Income (I+II)	16,123.68	12,551.39	12,030.42	45,313.43	38,686.16
IV	Expenses					
	Cost of materials consumed	7,127.45	8,165.02	8,545.20	27,045.00	24,885.99
	Changes in inventories of finished goods and work-in-progress	3,906.16	126.16	(1,191.55)	2,796.44	4,807.63
	Employee benefits expense	1,632.12	1,578.02	1,442.52	6,290.81	6,110.45
	Finance costs	793.33	717.67	1,040.23	3,456.76	3,670.70
	Depreciation and amortisation expense	1,178.82	1,123.77	1,159.13	4,499.34	4,377.40
	Other expenses	2,280.29	2,203.29	2,604.18	9,132.84	8,945.81
	Total expenses (IV)	16,918.17	13,913.93	13,599.71	53,221.19	52,797.98
V	Loss before exceptional items and tax (III - IV)	(794.49)	(1,362.54)	(1,569.29)	(7,907.76)	(14,111.82)
VI	Exceptional Items (Note 4)	-	209.43	-	209.43	-
VII	Loss before tax (V-VI)	(794.49)	(1,571.97)	(1,569.29)	(8,117.19)	(14,111.82)
VIII	Tax Expense:					
	(1) Current tax	-	-	-	-	-
	(2) Deferred tax expense/(income)	(16.31)	-	40.56	(16.31)	(631.00)
IX	Loss for the period/year (VII - VIII)	(778.18)	(1,571.97)	(1,609.85)	(8,100.88)	(13,480.82)
X	Other Comprehensive Income					
	A (i) Items that will not be reclassified to profit or loss	38.04	15.48	(17.96)	64.80	22.56
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(16.31)	-	(5.68)	(16.31)	(5.68)
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
XI	Total Comprehensive Loss for the period/year (IX + X) (Comprising loss and Other Comprehensive Income for the period/year)	(756.45)	(1,556.49)	(1,633.49)	(8,052.39)	(13,463.94)
XII	Paid-up Equity Share Capital (Face Value of Rs. 10/- per share)	2,228.22	2,228.17	1,961.14	2,228.22	1,961.14
XIII	Other Equity excluding Revaluation Reserve				36,758.42	21,446.25
XIV	Earnings per equity share (Face Value of Rs. 10/- per share) (for continuing & discontinuing operations) (non-annualised) :					
	(1) Basic (in Rs.)	(3.49)	(7.06)	(8.21)	(37.83)	(68.74)
	(2) Diluted (in Rs.)	(3.49)	(7.05)	(8.21)	(37.83)	(68.74)

Notes:

- The above Financial Results which are published in accordance with Regulations 33 and Regulations 52 (4) read with regulation 63 of the Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015 have been reviewed by the Audit Committee and have been approved by the Board of Directors at its Meeting held on Monday, 27th April 2026. The Financial Results are in accordance with the Indian Accounting Standards (Ind AS) as prescribed under section 133 of the Companies Act, 2013 ("Act"), read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 (including any amendment(s) / modification(s) / re-enactment(s) thereto). The Financial Results have been subjected to an Audit by the Statutory Auditors of the Company and they have expressed an unmodified audit opinion.
- The Company has only one reportable segment i.e. Agrochemicals as per Ind AS 108 "Operating Segments" specified under Section 133 of the Companies Act, 2013.
- On dated 30th June 2025 and 2nd July 2025, The Rights Issue Committee of the board of directors ("Rights Issue Committee") approved various terms of the Rights Issue and the Letter of Offer respectively, for issue of 28,01,673 fully paid-up Equity Shares at an issue price of Rs.890 per Equity Share (face value of Rs.10 per share and a premium of Rs.880 per share) ("fully paid-up equity shares"). Accordingly, the Rights Issue Committee on 29th July 2025 inter-alia, considered and approved the allotment of 26,69,951 fully paid-up equity shares to eligible equity shareholders on application ("Allotment"). There has been no deviation in the use of proceeds of the Rights Issue, from the objects stated in the Offer document.
- On 21st November 2025, the Government of India notified the four Labour Codes consolidating 29 existing labour laws. The Ministry of Labour & Employment published draft Central Rules and FAQs to enable assessment of the financial impact due to changes in regulations. The Group has assessed and disclosed the incremental impact of these changes on the basis of best information available, consistent with the guidance provided by the Institute of Chartered Accountants of India (ICAI). Considering the materiality and regulatory-driven, non-recurring nature of this impact, the Group has presented such incremental impact under "Exceptional Items" in the statement of profit and loss for the year ended 31st March 2026. The incremental impact consisting of gratuity of Rs. 172.80 Lakh and long-term compensated absences of Rs. 36.63 lakh primarily arises due to change in wage definition. The Company continues to monitor the finalisation of Central / State Rules and clarifications from the Government on other aspects of the Labour Code and would provide appropriate accounting effect on the basis of such developments as needed.
- The figures for the quarter ended March 31, 2026 and March 31, 2025 are the balancing figures between the audited figures in respect of the full financial year and the published unaudited year to date figures upto the third quarter of the respective financial year. Also the figures upto the third quarter of the respective financial year had only been reviewed and not subjected to audit.

For Astec LifeSciences Limited

 Digitally signed by
 Arijit Mukherjee
 Date: 2026.04.27
 17:49:33 +05'30'

Arijit Mukherjee
 Executive Director & Chief Operating Officer
 DIN: 07334111
 Place : Karjat
 Date : 27th April 2026

 Digitally signed by
 Rahul Choudhary
 Date: 2026.04.27
 18:02:53 +05'30'

Rahul Choudhary

(Rs. in Lakh)

Sr. No	Particulars	STANDALONE				
		Quarter ended			Year ended	
		31/Mar/26	31/Dec/25	31/Mar/25	31/Mar/26	31/Mar/25
		(Refer Note 5)	(Unaudited)	(Refer Note 5)	(Audited)	(Audited)
I	Current Ratio (refer note 1)	0.88	1.02	0.93	0.88	0.93
II	Net Worth (in Rs. Lakh)	38,986.64	39,768.20	23,407.39	38,986.64	23,407.39
III	Outstanding redeemable preference shares (quantity and value)	-	-	-	-	-
IV	Net profit/(loss) after tax (in Rs. Lakh)	(778.18)	(1,571.97)	(1,609.85)	(8,100.88)	(13,480.82)
V	Basic Earnings per share	(3.49)	(7.06)	(8.21)	(37.83)	(68.74)
VI	Diluted Earnings per share	(3.49)	(7.05)	(8.21)	(37.83)	(68.74)
VII	Capital Redemption Reserve (in Rs. Lakh)	0.30	0.30	0.30	0.30	0.30
VIII	Debt Equity ratio (refer note 1)	1.15	1.08	2.37	1.15	2.37
IX	Debt Service Coverage Ratio (DSCR) (refer note 1)	0.66	0.36	0.52	(0.01)	(1.15)
X	Interest Service Coverage Ratio (ISCR) (refer note 1)	1.50	0.38	0.54	(0.04)	(1.48)
XI	Long term debt to working capital (refer note 1)	4.49	3.65	*	4.49	*
XII	Bad debts to Account receivable ratio (refer note 1)	-	-	-	-	-
XIII	Current liability ratio (refer note 1)	0.74	0.71	0.55	0.74	0.55
XIV	Total debts to total assets (refer note 1)	0.48	0.46	0.63	0.48	0.63
XV	Debtors turnover (refer note 1)	2.87	3.03	3.50	2.25	2.35
XVI	Inventory turnover (refer note 1)	4.02	2.83	3.06	3.01	2.14
XVII	Operating margin (%)	5.78%	1.52%	4.62%	-1.47%	-17.36%
XVIII	Net profit/(loss) margin (%)	-4.91%	-12.60%	-13.47%	-18.08%	-35.35%

* Working Capital is negative

1 Pursuant to SEBI Operational Circular for Issue and Listing of Non-Convertible Securities, Securitised Debt Instruments, Security Receipts, Municipal Debt Securities and Commercial Paper dated 10th August 2021, the Company has listed Commercial Papers on National Stock Exchange (NSE).

The Company is rated by leading credit agency ICRA and India Ratings & Research. ICRA has assigned the rating “[ICRA] A1+” and “[ICRA] AA-” for its short term facilities (including commercial paper) and long term facilities respectively. India Ratings & Research has assigned “[IND] AA-” for its Non-Convertible Debentures (NCDs).

Formulae for computation of ratios:

Current ratio : Current assets / Current liabilities

Net Worth: Total equity

Debt Equity ratio : Total Debt / Shareholder’s Equity

Debt Service Coverage Ratio : (Net Profit after taxes + Non-cash operating expenses like depreciation and other amortizations + Interest + other adjustments like loss on sale of Fixed assets/Investment etc.) / (Interest & Lease Payments + Principal Repayments)

Interest service coverage ratio: (Net Profit after taxes + Non-cash operating expenses like depreciation and other amortizations + Interest + other adjustments like loss on sale of Fixed assets/Investment etc.) / Interest expense

Long term debt to working capital : (Non-current borrowings+Current maturities of long term debt) / (Current Assets - (Current liabilities-Current maturities of long term debt))

Bad debts to Account receivable ratio : Bad debts including provision for doubtful debts / Average Trade receivable.

Current liability ratio : (Current liabilities-Current maturities of Long term Debt) / Total liabilities

Total debts to total assets : Total borrowings / Total assets

Debtors turnover : Net Credit Sales / Average Trade Receivable (annualised)

Inventory turnover : Net Sales/ Average Inventory (annualised).

Operating margin (%): Earnings before Interest, Tax & Depreciation & Amortisation less Other Income/Revenue from Operations

Net Profit/(Loss) margin(%): Profit/Loss after Tax(after exceptional items)/Revenue from Operations

Arijit
Mukherjee

Digitally signed by
Arijit Mukherjee
Date: 2026.04.27
17:49:55 +05'30'

Rahul
Choudhary

Digitally signed by
Rahul Choudhary
Date: 2026.04.27
18:03:14 +05'30'

Statement of Audited Consolidated Financial Results for the Quarter and Year ended 31st March 2026

(Rs. in Lakh)

Sr. No	Particulars	Consolidated				
		Quarter ended			Year ended	
		31/Mar/26	31/Dec/25	31/Mar/25	31/Mar/26	31/Mar/25
		(Refer Note 5)	(Unaudited)	(Refer Note 5)	(Audited)	(Audited)
I	Revenue from Operations	15,862.26	12,472.03	11,952.70	44,814.56	38,130.35
II	Other Income	263.36	81.52	79.12	507.09	562.87
III	Total Income (I+II)	16,125.62	12,553.55	12,031.82	45,321.65	38,693.22
IV	Expenses					
	Cost of materials consumed	7,127.45	8,165.02	8,545.20	27,045.01	24,885.98
	Changes in inventories of finished goods and work-in-progress	3,906.17	126.16	(1,191.55)	2,796.44	4,807.63
	Employee benefits expense	1,632.12	1,578.02	1,442.52	6,290.81	6,110.45
	Finance costs	792.22	716.55	1,039.98	3,452.89	3,669.67
	Depreciation and amortisation expense	1,176.97	1,121.92	1,157.65	4,492.18	4,371.45
	Other expenses.	2,280.70	2,203.96	2,604.12	9,134.90	8,946.96
	Total expenses (IV)	16,915.63	13,911.63	13,597.92	53,212.23	52,792.14
V	Loss before exceptional items and tax (III - IV)	(790.01)	(1,358.08)	(1,566.10)	(7,890.58)	(14,098.92)
VI	Exceptional Items (Note 4)	-	209.43	-	209.43	-
VII	Loss before tax (V-VI)	(790.01)	(1,567.51)	(1,566.10)	(8,100.01)	(14,098.92)
VIII	Tax Expense:					
	(1) Current tax	0.99	1.01	1.40	4.00	3.91
	(2) Deferred tax expense/(income)	(16.30)	0.01	40.40	(16.39)	(631.66)
IX	Loss for the period/year (VII-VIII)	(774.70)	(1,568.53)	(1,607.90)	(8,087.62)	(13,471.17)
X	Other Comprehensive Income					
	A (i) Items that will not be reclassified to profit or loss	38.04	15.48	(17.96)	64.80	22.56
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(16.31)	-	(5.68)	(16.31)	(5.68)
	B (i) Items that will be reclassified to profit or loss	(0.70)	(1.68)	(0.40)	(2.32)	0.50
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
XI	Total Comprehensive Loss for the period/year (IX + X) (Comprising Loss) and Other Comprehensive Income for the period/year)	(753.67)	(1,554.73)	(1,631.94)	(8,041.45)	(13,453.79)
XII	Net Profit/(loss) attributable to:					
	- Owners	(775.73)	(1,569.54)	(1,608.76)	(8,091.75)	(13,475.24)
	- Non controlling interests	1.03	1.01	0.86	4.13	4.07
	Total Comprehensive loss attributable to:	(754.70)	(1,555.74)	(1,632.80)	(8,045.58)	(13,457.86)
	- Owners	(754.70)	(1,555.74)	(1,632.80)	(8,045.58)	(13,457.86)
	- Non controlling interests	1.03	1.01	0.86	4.13	4.07
XIII	Paid-up Equity Share Capital (Face Value of Rs.10/- per share)	2,228.22	2,228.17	1,961.14	2,228.22	1,961.14
XIV	Other Equity excluding Revaluation Reserve				36,832.36	21,513.38
XV	Earnings per equity share (Face Value of Rs.10/- per share) (non-annualised) :					
	(1) Basic (in Rs.)	(3.48)	(7.04)	(8.20)	(37.79)	(68.71)
	(2) Diluted (in Rs.)	(3.48)	(7.04)	(8.20)	(37.79)	(68.71)

Notes:

- The above Financial Results which are published in accordance with Regulations 33 and Regulations 52 (4) read with regulation 63 of the Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015 have been reviewed by the Audit Committee and have been approved by the Board of Directors at its Meeting held on Monday, 27th April 2026. The Financial Results are in accordance with the Indian Accounting Standards (Ind AS) as prescribed under section 133 of the Companies Act, 2013 ("Act"), read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 (including any amendment(s) / modification(s) / re-enactment(s) thereto). The Financial Results have been subjected to an Audit by the Statutory Auditors of the Group and they have expressed an unmodified audit opinion.
- The Group has only one reportable segment i.e. Agrochemicals as per Ind AS 108 "Operating Segments" specified under Section 133 of the Companies Act, 2013.
- On 30th June 2025 and 2nd July 2025, The Rights Issue Committee of the board of directors ("Rights Issue Committee") approved various terms of the Rights Issue and the Letter of Offer respectively, for issue of 28,01,673 fully paid-up Equity Shares at an issue price of Rs.890 per Equity Share (face value of Rs.10 per share and a premium of Rs.880 per share) ("fully paid-up equity shares"). Accordingly, the Rights Issue Committee on 29th July 2025 inter-alia, considered and approved the allotment of 26,69,951 fully paid-up equity shares to eligible equity shareholders on application ("Allotment"). There has been no deviation in the use of proceeds of the Rights Issue, from the objects stated in the Offer document.
- On 21st November 2025, the Government of India notified the four Labour Codes consolidating 29 existing labour laws. The Ministry of Labour & Employment published draft Central Rules and FAQs to enable assessment of the financial impact due to changes in regulations. The Group has assessed and disclosed the incremental impact of these changes on the basis of best information available, consistent with the guidance provided by the Institute of Chartered Accountants of India (ICAI). Considering the materiality and regulatory-driven, non-recurring nature of this impact, the Group has presented such incremental impact under "Exceptional Items" in the statement of profit and loss for the year ended 31st March 2026. The incremental impact consisting of gratuity of Rs. 172.80 lakh and long-term compensated absences of Rs. 36.63 lakh primarily arises due to change in wage definition. The Company continues to monitor the finalisation of Central / State Rules and clarifications from the Government on other aspects of the Labour Code and would provide appropriate accounting effect on the basis of such developments as needed.
- The figures for the quarter ended March 31, 2026 and March 31, 2025 are the balancing figures between the audited figures in respect of the full financial year and the published unaudited year to date figures upto the third quarter of the respective financial year. Also the figures upto the third quarter of the respective financial year had only been reviewed and not subjected to audit.

For Astec LifeSciences Limited

 Arijit Mukherjee
 Digitally signed by Arijit Mukherjee
 Date: 2026.04.27 17:50:14 +05'30'

 Arijit Mukherjee
 Executive Director & Chief Operating Officer
 DIN: 07334111
 Place : Karjat
 Date : 27th April 2026

 Rahul Choudhary
 Digitally signed by Rahul Choudhary
 Date: 2026.04.27 18:03:34 +05'30'

Additional disclosures as per Clause 52(4) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015
(Rs. in Lakh)

Sr. No	Particulars	Consolidated				
		Quarter ended			Year ended	
		31/Mar/26 (Refer Note 5)	31/Dec/25 (Unaudited)	31/Mar/25 (Refer Note 5)	31/Mar/26 (Audited)	31/Mar/25 (Audited)
I	Current Ratio (refer note 1)	0.89	1.02	0.93	0.89	0.93
II	Net Worth (in Rs. Lakh)	39,091.84	39,870.62	23,474.53	39,091.79	23,474.52
III	Outstanding redeemable preference shares (quantity and value)	-	-	-	-	-
IV	Net profit/(loss) after tax (in Rs. Lakh)	(774.70)	(1,568.53)	(1,607.90)	(8,087.62)	(13,471.17)
V	Basic Earnings per share	(3.48)	(7.04)	(8.20)	(37.79)	(68.71)
VI	Diluted Earnings per share	(3.48)	(7.04)	(8.20)	(37.79)	(68.71)
VII	Capital Redemption Reserve (in Rs. Lakh)	0.30	0.30	0.30	0.30	0.30
VIII	Debt Equity ratio (refer note 1)	1.15	1.08	2.36	1.15	2.36
IX	Debt Service Coverage Ratio (DSCR) (refer note 1)	0.66	0.37	0.53	(0.01)	(1.15)
X	Interest Service Coverage Ratio (ISCR) (refer note 1)	1.51	0.38	0.54	(0.04)	(1.48)
XI	Long term debt to working capital (refer note 1)	4.31	3.54	*	4.31	*
XII	Bad debts to Account receivable ratio (refer note 1)	-	-	-	-	-
XIII	Current liability ratio (refer note 1)	0.75	0.71	0.55	0.75	0.55
XIV	Total debts to total assets (refer note 1)	0.48	0.46	0.63	0.48	0.63
XV	Debtors turnover (refer note 1)	2.87	3.03	3.50	2.25	3.14
XVI	Inventory turnover (refer note 1)	4.02	2.83	3.06	3.01	2.14
XVII	Operating margin (%)	5.77%	1.52%	4.62%	-1.48%	-17.36%
XVIII	Net profit/(loss) margin (%)	-4.88%	-12.58%	-13.45%	-18.05%	-35.33%

***Working Capital is negative**

1 Pursuant to SEBI Operational Circular for Issue and Listing of Non-Convertible Securities, Securitised Debt Instruments, Security Receipts, Municipal Debt Securities and Commercial Paper dated 10th August 2021, the Company has listed Commercial Papers on National Stock Exchange (NSE).

The Company is rated by leading credit agency ICRA and India Ratings & Research. ICRA has assigned the rating “[ICRA] A1+” and “[ICRA] AA-” for its short term facilities (including commercial paper) and long term facilities respectively. India Ratings & Research has assigned “[IND] AA- “ for its Non- Convertible Debentures (NCDs).

Formulae for computation of ratios:

Current ratio : Current assets / Current liabilities

Net Worth: Total equity

Debt Equity ratio : Total Debt / Shareholder’s Equity

Debt Service Coverage Ratio : (Net Profit after taxes + Non-cash operating expenses like depreciation and other amortizations + Interest + other adjustments like loss on sale of Fixed assets/Investment etc.) / (Interest & Lease Payments + Principal Repayments)

Interest service coverage ratio: (Net Profit after taxes + Non-cash operating expenses like depreciation and other amortizations + Interest + other adjustments like loss on sale of Fixed assets/Investment etc.) / Interest expense

Long term debt to working capital : (Non-current borrowings+Current maturities of long term debt) / (Current Assets - (Current liabilities-Current maturities of long term debt))

Bad debts to Account receivable ratio : Bad debts including provision for doubtful debts / Average Trade receivable.

Current liability ratio : (Current liabilities-Current maturities of Long term Debt) / Total liabilities

Total debts to total assets : Total borrowings / Total assets

Debtors turnover : Net Credit Sales / Average Trade Receivable (annualised)

Inventory turnover : Net Sales/ Average Inventory (annualised).

Operating margin (%): Earnings before Interest, Tax & Depreciation & Amortisation less Other Income/Revenue from Operations

Net Profit/ (Loss) margin(%): Profit/Loss after Tax(after exceptional items)/Revenue from Operations

**Arijit
Mukherjee**

Digitally signed by
Arijit Mukherjee
Date: 2026.04.27
17:50:30 +05'30'

**Rahul
Choudhary**

Digitally signed by
Rahul Choudhary
Date: 2026.04.27
18:03:58 +05'30'

(Rs. in Lakh)

PARTICULARS	STANDALONE		CONSOLIDATED	
	As at 31st March 2026 (Audited)	As at 31st March 2025 (Audited)	As at 31st March 2026 (Audited)	As at 31st March 2025 (Audited)
ASSETS				
(1) Non-current assets				
(a) Property, Plant and Equipment	42,337.79	46,591.73	42,357.89	46,612.64
(b) Capital work-in-progress	19.57	12.51	19.57	12.51
(c) Right of use assets	3,035.43	3,041.63	3,005.22	3,044.88
(d) Other Intangible assets	534.68	220.10	534.68	220.10
(e) Intangible assets under development	1,940.78	2,124.75	1,940.78	2,124.75
(f) Financial Assets				
(i) Investments in Subsidiaries	42.18	42.18	-	-
(ii) Other Investments	0.53	0.53	0.53	0.53
(iii) Other non-current financial assets	134.64	136.29	134.64	136.29
(g) Other non-current tax assets (net)	879.70	823.57	880.60	824.46
(h) Other non-current assets	1,030.80	1,052.44	1,030.80	1,052.44
Total Non-current assets	49,956.10	54,045.73	49,904.71	54,028.60
(2) Current Assets				
(a) Inventories	13,803.32	15,981.07	13,803.32	15,981.07
(b) Financial Assets				
(i) Trade Receivables	24,771.68	14,744.27	24,771.68	14,744.27
(ii) Cash and cash equivalents	1,003.70	56.50	1,004.90	57.54
(iii) Bank balances other than (ii) above	93.25	93.24	220.19	213.00
(iv) Loans	261.12	277.18	261.12	277.18
(v) Others financial assets	105.18	64.18	105.18	64.18
(c) Other current assets	4,128.08	2,779.59	4,132.72	2,776.54
Total Current Assets	44,166.33	33,996.03	44,299.11	34,113.78
Total Assets	94,122.43	88,041.76	94,203.82	88,142.38
EQUITY AND LIABILITIES				
Equity				
(a) Equity Share capital	2,228.22	1,961.14	2,228.22	1,961.14
(b) Other Equity	36,758.42	21,446.25	36,832.36	21,513.38
(c) Non controlling interest	-	-	31.26	27.13
Total Equity	38,986.64	23,407.39	39,091.84	23,501.65
LIABILITIES				
(1) Non-current liabilities				
(a) Financial Liabilities				
(i) Borrowings	5,000.00	28,000.00	5,000.00	28,000.00
(ii) Lease liabilities	28.61	-	-	-
(iii) Other financial liabilities	-	29.00	-	29.00
(b) Provisions	129.62	36.67	129.62	36.67
(c) Deferred tax liabilities (net)	-	-	3.72	3.80
Total Non Current Liabilities	5,158.23	28,065.67	5,133.34	28,069.47
(2) Current Liabilities				
(a) Financial Liabilities				
(i) Borrowings	39,892.99	27,454.41	39,892.99	27,454.41
(ii) Lease liabilities	7.55	1.65	-	-
(iii) Trade payables				
Total outstanding dues of Micro Enterprises and Small Enterprises	749.58	413.63	749.58	413.63
Total outstanding dues of creditors other than Micro Enterprises and Small Enterprises	8,011.17	7,745.39	8,016.95	7,747.64
(iv) Other financial liabilities	938.31	684.41	940.57	686.19
(b) Other current liabilities	134.75	171.41	135.34	171.59
(c) Provisions	243.21	97.80	243.21	97.80
Total Current Liabilities	49,977.56	36,568.70	49,978.64	36,571.26
Total liabilities	55,135.79	64,634.37	55,111.98	64,640.73
Total Equity and Liabilities	94,122.43	88,041.76	94,203.82	88,142.38

For Astec LifeSciences Limited

Arijit Mukherjee
Digitally signed by
Arijit Mukherjee
Date: 2026.04.27
17:50:48 +05'30'

Arijit Mukherjee
Executive Director & Chief Operating Officer
DIN: 07334111
Place : Karjat
Date : 27th April 2026

Rahul Choudhary
Digitally signed by
Rahul Choudhary
Date: 2026.04.27
18:04:20 +05'30'

PARTICULARS	STANDALONE		CONSOLIDATED	
	Year ended		Year ended	
	31st March 2026	31st March 2025	31st March 2026	31st March 2025
	(Audited)	(Audited)	(Audited)	(Audited)
I Cash flow from operating activities				
Loss before tax	(8,117.19)	(14,111.82)	(8,100.01)	(14,098.92)
Adjustments for				
Depreciation and amortisation expense	4,499.34	4,377.40	4,492.18	4,371.45
Interest income	(43.83)	(73.26)	(52.05)	(80.32)
Finance cost paid	3,456.76	3,670.70	3,452.89	3,669.67
Unrealised foreign exchange (loss)/gain (net)	(224.78)	323.17	(224.78)	323.17
Loss allowance - trade receivables	80.66	4.75	80.66	4.75
Loss/(Gain) on sale of property, plant and equipment	6.59	(201.81)	6.59	(201.81)
Provision for Inventories	114.28	2,016.81	114.28	2,016.81
Employee stock options expense	9.25	3.45	9.25	3.45
	7,898.27	10,121.21	7,879.02	10,107.17
Operating Profit Before Working Capital Changes	(218.92)	(3,990.61)	(220.99)	(3,991.75)
Adjustments for				
Decrease/(Increase) in trade receivables	(9,208.18)	1,888.34	(9,208.17)	1,888.36
Decrease/(Increase) in loans	16.06	(273.14)	16.06	(273.14)
(Increase)/Decrease in other financial assets	(47.37)	169.41	(47.37)	169.40
(Increase)/Decrease in other current assets	(1,348.51)	143.40	(1,358.53)	143.86
(Increase)/Decrease in inventories	2,063.46	1,586.78	2,063.47	1,586.78
(Increase)/Decrease in other financial assets-non-current	17.68	17.00	17.68	17.00
Increase/(Decrease) in trade payables	429.08	(779.38)	432.61	(775.32)
(Decrease)/Increase in other financial liabilities	56.23	51.93	56.72	51.58
(Decrease)/Increase in other current liabilities	(36.65)	43.20	(36.25)	43.28
(Decrease)/Increase in provisions	303.15	(23.07)	303.16	(23.08)
Increase/(Decrease) in other non-current financial liabilities	(29.00)	(176.00)	(29.00)	(176.00)
Cash generated from operations	(8,002.97)	(1,342.14)	(8,010.61)	(1,339.03)
Direct Taxes paid (net of refunds received)	(56.13)	503.14	(60.14)	499.17
Net cash flow (used in)/generated from in Operating activities	(8,059.10)	(839.00)	(8,070.75)	(839.86)
II Cash flow from investing activities				
Acquisition of property, plant and equipment and capital work-in-progress	(553.58)	(2,182.20)	(553.60)	(2,182.19)
Proceeds from sale of property, plant and equipment	70.13	596.77	70.13	596.77
Deposits redeemed / (placed)	-	0.19	(7.19)	(16.91)
Interest received	51.85	72.24	60.07	79.30
Net cash flow used in Investing activities	(431.60)	(1,513.00)	(430.59)	(1,523.03)
III Cash flow from financing activities				
Proceeds of Long term borrowings	-	15,100.00	-	15,100.00
Repayment of Long term Borrowings	(11,211.63)	(6,076.09)	(11,211.63)	(6,076.09)
Proceeds/(Repayment) of short term borrowings (net)	5,197.08	(2,695.46)	5,197.09	(2,695.46)
Proceeds from issue of shares	23,622.40	0.23	23,622.40	0.23
Payment of lease liabilities	(6.93)	(9.77)	-	-
Payment of Interest on lease liabilities	(3.88)	(1.03)	-	-
Intercorporate deposits taken Long term	-	1,000.00	-	1,000.00
Intercorporate deposits repaid Long term	(3,900.00)	(2,100.00)	(3,900.00)	(2,100.00)
Intercorporate deposits taken/(repaid) short term	(1,000.00)	1,000.00	(1,000.00)	1,000.00
Finance cost paid	(3,259.15)	(3,855.43)	(3,259.16)	(3,855.40)
Net cash flow generated from / (used in) Financing activities	9,437.90	2,362.46	9,448.70	2,373.28
Net increase / (decrease) in cash and cash equivalents	947.20	10.45	947.36	10.39
Cash and cash equivalents as at the beginning of the year	56.50	46.05	57.54	47.15
Cash and cash equivalents as at the end of the period	1,003.70	56.50	1,004.90	57.54

For Astec LifeSciences Limited

Arijit Mukherjee
Digitally signed by Arijit Mukherjee
Date: 2026.04.27
17:51:08 +05'30'

Arijit Mukherjee
Executive Director & Chief Operating Officer
DIN: 07334111
Place : Karjat
Date : 27th April 2026

Rahul Choudhary
Digitally signed by Rahul Choudhary
Date: 2026.04.27
18:04:50 +05'30'